Orisett is backed by two human trials.
NutraGenesis LLC (Brattleboro, VT) is ready to market a crab shell ingredient for blood sugar control. Called Orisett, the water-soluble powder contains chitosan bioactives and is backed by animal and human studies.
In a “gold standard” trial, Orisett improved insulin sensitivity and lowered glucose spikes over long-term durations and immediately after eating periods. The company says one of the ingredient’s mechanisms of action is its ability to block alpha-glucosidase, an enzyme that allows the body to digest sugar. Several studies also confirm the safety of this ingredient, says the company.
Nutragenesis is supplying the crab shell ingredient through a partnership with Kunpoong Bio Company Ltd. of South Korea. Orisett can be formulated in product formats such as capsules, tablets, gummies, stick packs, and snack bars.